Recurrence and Mortality Rates Among Receivers and Decliners of Conventional Adjuvant Breast Cancer Treatments

Eunjung Kim, L. Standish, M. Andersen
{"title":"Recurrence and Mortality Rates Among Receivers and Decliners of Conventional Adjuvant Breast Cancer Treatments","authors":"Eunjung Kim, L. Standish, M. Andersen","doi":"10.33805/2689-6737.108","DOIUrl":null,"url":null,"abstract":"Objectives:\nThis paper compared Recurrence and Morality rates among women with breast cancer who received all recommended treatment (Receivers) and who did not (Decliners).\nMethods:\n427 women were recruited through integrative oncology clinics and the Cancer Surveillance System (CSS) registry in Western Washington State. Secondary data analysis were conducted using descriptive statistics, t-tests, X2 tests, and R. Self-reported data included household income and comorbidity; medical records included dates of diagnosis, recurrence and last visit with medical oncologist; and CSS registry data included demographic, disease characteristics, and records on recommended treatments and receiving/declining them, and date of death.\nResults:\n9% of Receivers and 2% of Decliners experienced a Disease Free Survival (DFS) limiting event commonly a recurrence, while 3% of Receivers and 2% of Decliners died. After controlling for stage at diagnosis and cohort, no difference was found on the Adjusted Hazard ratio of recurrence or mortality between Receivers and Decliners. Adjusted Hazard ratio of Decliners relative to Receivers was 0.29 (95% CI; 0.04 – 2.22, p = 0.22) for DFS and 0.50 (95% CI: 0.04, 6.49, p = 0.59) for mortality.\nConclusions:\nBetter clinical predictors among Decliners may be related to no rate difference in recurrence and mortality between Decliners than Receivers.","PeriodicalId":316427,"journal":{"name":"Edelweiss: Cancer Open Access","volume":"8 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2019-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Edelweiss: Cancer Open Access","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33805/2689-6737.108","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: This paper compared Recurrence and Morality rates among women with breast cancer who received all recommended treatment (Receivers) and who did not (Decliners). Methods: 427 women were recruited through integrative oncology clinics and the Cancer Surveillance System (CSS) registry in Western Washington State. Secondary data analysis were conducted using descriptive statistics, t-tests, X2 tests, and R. Self-reported data included household income and comorbidity; medical records included dates of diagnosis, recurrence and last visit with medical oncologist; and CSS registry data included demographic, disease characteristics, and records on recommended treatments and receiving/declining them, and date of death. Results: 9% of Receivers and 2% of Decliners experienced a Disease Free Survival (DFS) limiting event commonly a recurrence, while 3% of Receivers and 2% of Decliners died. After controlling for stage at diagnosis and cohort, no difference was found on the Adjusted Hazard ratio of recurrence or mortality between Receivers and Decliners. Adjusted Hazard ratio of Decliners relative to Receivers was 0.29 (95% CI; 0.04 – 2.22, p = 0.22) for DFS and 0.50 (95% CI: 0.04, 6.49, p = 0.59) for mortality. Conclusions: Better clinical predictors among Decliners may be related to no rate difference in recurrence and mortality between Decliners than Receivers.
乳腺癌常规辅助治疗的接受者和放弃者的复发率和死亡率
目的:本文比较了接受所有推荐治疗的乳腺癌妇女(接受者)和未接受推荐治疗的乳腺癌妇女(下降者)的复发率和死亡率。方法:通过华盛顿州西部的综合肿瘤学诊所和癌症监测系统(CSS)登记处招募了427名妇女。二次资料分析采用描述性统计、t检验、X2检验和r。自述资料包括家庭收入和合并症;医疗记录包括诊断、复发和最后一次肿瘤医生就诊日期;CSS登记数据包括人口统计、疾病特征、推荐治疗和接受/拒绝治疗的记录以及死亡日期。结果:9%的接受者和2%的衰退者经历无病生存(DFS)限制事件,通常为复发,而3%的接受者和2%的衰退者死亡。在控制了诊断阶段和队列后,在接受者和下降者之间的复发率或死亡率的调整风险比上没有发现差异。衰退者相对于接受者的调整风险比为0.29 (95% CI;DFS为0.04 - 2.22,p = 0.22),死亡率为0.50 (95% CI: 0.04, 6.49, p = 0.59)。结论:衰退患者中更好的临床预测指标可能与衰退患者与接受患者之间的复发率和死亡率无差异有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信